logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany.

    Article - En anglais

    Background 

    The strategies for the management of onychomycosis have changed since the availability of the newer generation of antifungal agents, particularly, itraconazole and terbinafine.

    Itraconazole (1-week pulse) therapy may have higher efficacy and an improved adverse-effects profile compared to the continuous therapy regimen.

    Objective 

    We performed a pharmacoeconomic evaluation of the most commonly used treatments in Germany for toenail onychomycosis from a health care payer perspective.

    Methods 

    A 5-step approach was used.

    Firstly, the purpose of the study, the comparator drugs, their dosage regimens and the time frame of the analysis were defined.

    Next, the medical practice and resource consumption patterns associated with the treatment of onychomycosis were identified.

    In step III, a meta-analysis was used to determine the relative efficacy of the comparator drugs.

    In step IV, a decision tree of the treatment algorithms was constructed for each comparator.

    The expected cost analysis and cost-effectiveness analysis were also performed.

    Finally, a sensitivity analysis was carried out.

    Results 

    For the four main comparator drugs used to treat toenail onychomycosis in Germany, the clinical response rates (clinical cure plus marked improvement) at the end of the follow-up period (month 12 after starting therapy) were, for itraconazole (1-week pulse dosing) : 89.8 ± 3% (mean ± SE), terbinafine : 79.4 ± 10%, itraconazole (continuous dosing) : 77. (...)

    Mots-clés Pascal : Antifongique, Gros orteil, Mycose, Infection, Ongle, Allemagne, Europe, Economie santé, Itraconazole, Analyse coût efficacité, Aspect économique, Homme, Triazole dérivé

    Mots-clés Pascal anglais : Antifungal agent, Big toe, Mycosis, Infection, Nail(anatomy), Germany, Europe, Health economy, Cost efficiency analysis, Economic aspect, Human, Triazole derivatives

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0506805

    Code Inist : 002B02S04. Création : 10/04/1997.